文献速递妇科肿瘤

贝伐珠单抗联合紫杉醇-卡铂化疗及二次肿瘤细胞减灭术治疗铂敏感复发性卵巢癌(NRG肿瘤学/妇科肿瘤组研究GOG-0213):一项多中心、开放标签、随机、3期试验

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2017-04-21

GOG-0213研究在67个中心纳入674例铂敏感复发性卵巢癌患者,随机接受标准化疗或化疗联合贝伐珠单抗。贝伐珠单抗组中位总生存42.2个月 vs 化疗组37.3个月(HR 0.829,95%CI 0.683-1.005,P=0.056),意向治疗分析未达统计学显著;基于校正分层数据的敏感性分析调整HR 0.823(95%CI 0.680-0.996,P=0.0447)。

要点

  • 贝伐珠单抗组中位总生存42.2个月 vs 化疗组37.3个月,HR 0.829(95%CI 0.683-1.005),意向治疗分析P=0.056未达显著。
  • 基于校正无治疗间期分层数据的敏感性分析调整HR 0.823(95%CI 0.680-0.996,P=0.0447)。
  • 贝伐珠单抗组3级及以上不良事件317/325例(96%) vs 化疗组282/332例(86%),高血压39例(12%) vs 2例(1%)。

核心结论

  • 在标准化疗基础上加用贝伐珠单抗并维持治疗至疾病进展,改善了铂敏感复发性卵巢癌患者的中位总生存。
  • 意向治疗分析的总生存未达统计学显著,但基于校正无治疗间期分层数据的敏感性分析提示该策略可能为这类患者的重要治疗选择。

研究设计与样本

  • 多中心、开放标签、随机3期试验,在美国65个中心、日本1个中心、韩国1个中心共67个中心开展。
  • 纳入674例成人女性(≥18岁)复发性可测量或可评估的上皮性卵巢癌、原发腹膜癌或输卵管癌,对初始化疗达临床完全缓解且末次铂类输注后无病生存至少6个月。
  • 随机(1:1)接受标准化疗(紫杉醇175 mg/m2体表面积联合卡铂AUC 5,每3周1次,共6周期)或相同化疗联合贝伐珠单抗15 mg/kg体重每3周1次并维持治疗至疾病进展或不可耐受毒性。
  • 随机按无治疗间期及是否参与手术目标分层,主要终点为总生存,采用意向治疗分析。
  • 2007年12月10日至2011年8月26日入组,试验结束时2014年11月5日中位随访49.6个月。

主要发现

  • 贝伐珠单抗组中位总生存42.2个月(95%CI 37.7-46.2) vs 化疗组37.3个月(95%CI 32.6-39.7),HR 0.829(95%CI 0.683-1.005,P=0.056)。
  • 45例(7%)患者无治疗间期分层数据不正确(两组均衡),基于稽查校正数据的敏感性分析调整HR 0.823(95%CI 0.680-0.996,P=0.0447)。
  • 安全性人群中,贝伐珠单抗组317/325例(96%) vs 化疗组282/332例(86%)发生至少1项3级及以上不良事件。
  • 贝伐珠单抗组 vs 化疗组最常见3级及以上不良事件:高血压39例(12%) vs 2例(1%),乏力27例(8%) vs 8例(2%),蛋白尿27例(8%) vs 0例。
  • 治疗相关死亡:化疗组2例(1%)(感染1例、骨髓增生异常综合征1例) vs 贝伐珠单抗组9例(3%)(感染1例、发热性中性粒细胞减少1例、骨髓增生异常综合征1例、第二恶性肿瘤1例;未按CTCAE分类的死亡:疾病进展3例、猝死1例、未指明1例)。

临床怎么用

  • 作者认为,尽管意向治疗分析的总生存未达统计学显著,基于校正无治疗间期分层数据的敏感性分析提示该策略可能为铂敏感复发性卵巢癌患者的重要治疗选择。

局限性

  • 45例(7%)患者无治疗间期分层数据不正确(两组均衡),意向治疗分析的总生存未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and report the results of the bevacizumab component here. METHODS: The multicentre, open-label, randomised phase 3 GOG-0213 trial was done in 67 predominantly academic centres in the USA (65 centres), Japan (one centre), and South Korea (one centre). Eligible patients were adult women (aged ≥18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer, and a clinical complete response to primary platinum-based chemotherapy, who had been disease-free for at least 6 months following last infused cycle of platinum. Patients were randomly assigned (1:1) to standard chemotherapy (six 3-weekly cycles of paclitaxel [175 mg/m2 of body surface area] and carboplatin [area under the curve 5]) or the same chemotherapy regimen plus bevacizumab (15 mg/kg of bodyweight) every 3 weeks and continued as maintenance every 3 weeks until disease progression or unacceptable toxicity. Individuals who participated in both the bevacizumab objective and surgical objective (which is ongoing) were randomly assigned (1:1:1:1) to receive either of these two chemotherapy regimens with or without prior secondary cytoreductive surgery. Randomisation for the bevacizumab objective was stratified by treatment-free interval and participation in the surgical objective. The primary endpoint was overall survival, analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00565851. FINDINGS: Between Dec 10, 2007, and Aug 26, 2011, 674 women were enrolled and randomly assigned to standard chemotherapy (n=337) or chemotherapy plus bevacizumab (n=377). Median follow-up at the end of the trial on Nov 5, 2014, was 49·6 months in each treatment group (IQR 41·5-62·2 for chemotherapy plus bevacizumab; IQR 40·8-59·3 for chemotherapy), at which point 415 patients had died (214 in the chemotherapy group and 201 in the chemotherapy plus bevacizumab group). Based on pretreatment stratification data, median overall survival in the chemotherapy plus bevacizumab group was 42·2 months (95% CI 37·7-46·2) versus 37·3 months (32·6-39·7) in the chemotherapy group (hazard ratio [HR] 0·829; 95% CI 0·683-1·005; p=0·056). We identified incorrect treatment-free interval stratification data for 45 (7%) patients (equally balanced between treatment groups); a sensitivity analysis of overall survival based on the audited treatment-free interval stratification data gave an adjusted HR of 0·823 (95% CI 0·680-0·996; p=0·0447). In the safety population (all patients who initiated treatment), 317 (96%) of 325 patients in the chemotherapy plus bevacizumab group had at least one grade 3 or worse adverse event compared with 282 (86%) of 332 in the chemotherapy group; the most frequently reported of these in the chemotherapy plus bevacizumab group compared with the chemotherapy group were hypertension (39 [12%] vs two [1%]), fatigue (27 [8%] vs eight [2%]), and proteinuria (27 [8%] vs none). Two (1%) treatment-related deaths occurred in the chemotherapy group (infection [n=1] and myelodysplastic syndrome [n=1]) compared with nine (3%) in the chemotherapy plus bevacizumab group (infection [n=1], febrile neutropenia [n=1], myelodysplastic syndrome [n=1], secondary malignancy [n=1]; deaths not classified with CTCAE terms: disease progression [n=3], sudden death [n=1], and not specified [n=1]). INTERPRETATION: The addition of bevacizumab to standard chemotherapy, followed by maintenance therapy until progression, improved the median overall survival in patients with platinum-sensitive recurrent ovarian cancer. Although the intention-to-treat analysis for overall survival was not significant, our sensitivity analysis based on corrected treatment-free interval stratification indicates that this strategy might be an important addition to the therapeutic armamentarium in these patients. FUNDING: National Cancer Institute and Genentech.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017. PMID: 28438473. doi:10.1016/S1470-2045(17)30279-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。